Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer-Reference-Cited by-同舟云学术

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer

Published:2020-05-01 Issue:5 Volume:6 Page:650
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Phillips Ryan¹,Shi William Yue²,Deek Matthew¹,Radwan Noura¹,Lim Su Jin³,Antonarakis Emmanuel S.³,Rowe Steven P.⁴⁵,Ross Ashley E.⁵,Gorin Michael A.⁴⁵,Deville Curtiland¹,Greco Stephen C.¹,Wang Hailun¹,Denmeade Samuel R.³,Paller Channing J.³,Dipasquale Shirl¹,DeWeese Theodore L.¹³⁵,Song Daniel Y.¹³⁵,Wang Hao³,Carducci Michael A.³,Pienta Kenneth J.³⁵,Pomper Martin G.⁴⁵,Dicker Adam P.⁶,Eisenberger Mario A.³,Alizadeh Ash A.⁷,Diehn Maximilian²,Tran Phuoc T.¹³⁵

Affiliation:

1. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland

2. Stanford Cancer Institute, Department of Radiation Oncology, School of Medicine, Stanford University, Stanford, California

3. Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland

4. The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland

5. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland

6. Sidney Kimmel Cancer Center, Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania

7. Stanford Cancer Institute, Division of Oncology, Department of Medicine, School of Medicine, Stanford University, Stanford, California

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2763312/jamaoncology_phillips_2020_oi_200004.pdf

Reference32 articles.

1. Targeting metastatic hormone sensitive prostate cancer: chemohormonal therapy and new combinatorial approaches.;Damodaran;J Urol,2019

2. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology.;Nuhn;Eur Urol,2019

3. Oligometastases.;Hellman;J Clin Oncol,1995

4. Consolidative radiotherapy for limited metastatic non–small-cell lung cancer: a phase 2 randomized clinical trial.;Iyengar;JAMA Oncol,2018

5. Local consolidative therapy vs maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study.;Gomez;J Clin Oncol,2019

Cited by 807 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stereotactic ablative radiotherapy for oligoprogressive solid tumours: A systematic review and meta-analysis;Radiotherapy and Oncology;2024-11

2. Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E2-RADIatE OligoCare cohort;Radiotherapy and Oncology;2024-10

3. Influence of Tumor Characteristics and Time to Metastatic Disease on Oncological Outcomes in Metachronous Metastatic Prostate Cancer Patients;Clinical Genitourinary Cancer;2024-10

4. Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomics;Radiotherapy and Oncology;2024-10

5. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer;Clinical and Translational Oncology;2024-09-12